BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present at the following events in September: H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, 2024) Format: Virtual Presentation: Available on-demand beginning Monday, September 9 ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. S ...

BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma. "Cholangiocarcinoma is a rare and aggressive form of cancer that presents a signific ...

Financial Data and Key Metrics Changes - Operating expenses for Q2 2024 totaled $5.5 million, a decrease of $1.4 million or 19.7% compared to $6.9 million in Q2 2023 [5][6] - Research and development expenses were approximately $2.6 million, down from $3.2 million in Q2 2023, representing a decrease of $0.6 million or 17.7% [6] - General and administrative expenses were approximately $2.9 million, a decrease of $0.8 million or 21.3% compared to $3.7 million in Q2 2023 [7] - Net losses were $5 million for Q2 2024, compared to $4 million for Q2 2023 [8] - As of June 30, 2024, the company had cash, cash equivalents, and marketable securities of approximately $38.3 million, expected to fund operations into early 2026 [8] Business Line Data and Key Metrics Changes - The company is focused on advancing its development pipeline centered around Certepetide for treating advanced solid tumors [4][5] - The ASCEND trial is a key study evaluating Certepetide in combination with standard chemotherapy for metastatic pancreatic cancer, with top-line data expected in Q4 2024 [22][23] Market Data and Key Metrics Changes - The company is pursuing multiple special regulatory designations for Certepetide, including fast track and orphan drug designations, which enhance its market position [17][18] Company Strategy and Development Direction - The company aims to optimize Certepetide's regulatory review and future commercialization through strategic design choices in clinical trials [10][20] - The development strategy includes rapid registration for pancreatic cancer and exploring partnerships to maximize the product's value [33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about Certepetide's potential to transform cancer treatment, with the upcoming ASCEND data readout seen as a critical moment for the company [33] - The company is committed to advancing Certepetide across multiple tumor types and exploring strategic partnerships [33] Other Important Information - Certepetide has shown favorable clinical safety and tolerability, with significant preclinical data supporting its efficacy in enhancing delivery of standard-of-care chemotherapy [16][17] Q&A Session Summary Question: Feedback from clinicians on enrollment and demand for Certepetide - Management received positive feedback from clinicians regarding the rapid enrollment and enthusiasm for Certepetide's potential impact on treatment outcomes [35] Question: Standard-of-care for cholangiocarcinoma - The current standard-of-care for cholangiocarcinoma includes gemcitabine, cisplatin, and durvalumab, with poor overall survival rates for patients [39] Question: Progress on Phase 2 trial in mPDAC - The independent company conducting the trial does not provide regular updates, but management expects to receive insights during quarterly joint steering committee meetings [42] Question: Enrollment updates for GBM trial - Enrollment updates for the GBM trial are pending, with expectations for increased enrollment as sites in Latvia are open [45] Question: Pediatric patient population in pancreatic cancer - The pediatric population for pancreatic cancer is extremely small, essentially close to zero [47] Question: Collaboration with other drug companies - Management confirmed ongoing dialogues with other companies regarding potential collaborations to enhance the efficacy of their products with Certepetide [48][49] Question: Intellectual property status - The company has a broad intellectual property portfolio covering Certepetide, with protections extending into the 2030s and potential extensions into the 2040s [51]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. S ...

Can you tell us more about Haystack Oncology and about the collaboration itself? What are some of the challenges in the development of anti-cancer therapies for tumors like pancreatic But why we're doing this? To further assess the dose and dose regimen of certepetide. We've designed a trial called Fortified. The trial is evaluating a different patient population, specifically patients with metastatic pancreatic cancer who have progressed on their first-line treatment of FOLFIRINOX. The trial has three coho ...

Use of technology About the publisher About Emily Jarvie Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that exci ...

Top-line data now anticipated mid-2025 The BOLSTER trial is a Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating certepetide in combination with standard-of-care (gemcitabine/cisplatin/durvalumab) versus standard-of-care alone in patients with first-line CCA in the United States. The rapid enrollment of this cohort underscores the urgent need for new treatment options for patients with CCA, a difficult-to-treat solid tumor with a poor prognosis. Based on this rapid enrollme ...

Group 1 - Proactive specializes in providing fast, accessible, and informative business and finance news content to a global investment audience [1][2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] - Proactive's news team operates from key finance and investing hubs worldwide, including London, New York, Toronto, Vancouver, Sydney, and Perth [4] Group 2 - The content produced by Proactive includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [5] - Proactive employs technology to enhance workflows, utilizing automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [6][7]

BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announces promising preclinical results for its investigational candidate, certepetide (formerly LSTA1). The data, presented in a poster by Dr. Dan G. Duda of Massachusetts General Hospital at the 2024 Cholangiocarcinoma Foundation Annual ...